• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Terlivaz (terlipressin) for injection

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Terlivaz (terlipressin) for injection

  • Profile

Profile

Contact Information

Contact: Mallinckrodt Pharmaceuticals
Website: www.terlivaz.com

Currently Enrolling Trials

    Show More

    General Information

    Terlivaz (terlipressin) is a vasopressin receptor agonist. 

    Terlivaz is specifically indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

    Terlivaz is supplied as an injection for intravenous administration. Terlivaz can cause serious or fatal respiratory failure. Obtain baseline oxygen saturation (SpO2) prior to administering the first dose of Terlivaz. During treatment, monitor patient oxygen saturation using continuous pulse oximetry. Do not use Terlivaz treatment in patients experiencing hypoxia until hypoxia resolves. Assess Acute-on-Chronic Liver Failure (ACLF) Grade and volume status before initiating Terlivaz.

    Recommended Dosage Regimen:

    Days 1 to 3 administer Terlivaz 0.85 mg (1 vial) intravenously every 6 hours.

    Day 4: Assess serum creatinine (SCr) versus baseline.

    • If SCr has decreased by at least 30% from baseline, continue Terlivaz 0.85 mg (1 vial) intravenously every 6 hours.
    • If SCr has decreased by less than 30% from baseline, dose may be increased to Terlivaz 1.7 mg (2 vials) intravenously every 6 hours.

    Mechanism of Action

    Terlivaz (terlipressin) is a vasopressin receptor agonist with twice the selectivity for vasopressin V1 receptors versus V2 receptors. Terlipressin acts as both a prodrug for lysine-vasopressin, as well as having pharmacologic activity on its own. Terlipressin is thought to increase renal blood flow in patients with hepatorenal syndrome by reducing portal hypertension and blood circulation in portal vessels and increasing effective arterial volume and mean arterial pressure.

    Side Effects

    Adverse effects associated with the use of Terlivaz may include, but are not limited to, the following:

    • abdominal pain
    • nausea
    • respiratory failure
    • diarrhea
    • dyspnea

    The Terlivaz drug label comes with the following Black Box Warning: Terlivaz may cause serious or fatal respiratory failure. Patients with volume overload or with ACLF Grade 3 are at increased risk. Assess oxygenation saturation (e.g., SpO2) before initiating Terlivaz. Do not initiate Terlivaz in patients experiencing hypoxia (e.g., SpO2 <90%) until oxygenation levels improve. Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue Terlivaz if SpO2 decreases below 90%.

    Clinical Trial Results

    The FDA approval was based, in part, on results from the Phase 3 CONFIRM trial, the largest-ever prospective study (n=300) conducted to assess the safety and efficacy of terlipressin in patients with HRS type 1 (HRS-1) in the U.S. and Canada. Patients in the study were critically ill, as indicated by assessments of their liver and kidney function at the start of the trial. 

    The study met its primary endpoint of Verified HRS Reversal (VHRSR), which is defined as renal function improvement, avoidance of dialysis and short-term survival. 29.1 percent (58/199) of patients administered terlipressin plus albumin achieved Verified HRS Reversal versus 15.8 percent (16/101) on placebo plus albumin. In order to achieve Verified HRS Reversal, patients had to have two consecutive SCr values ≤1.5 mg/dL, at least two hours apart by day 14 or hospital discharge and be alive without intervening renal replacement therapy (RRT) for at least 10 days following discharge or treatment.

    Approval Date: 2022-09-01
    Company Name: Mallinckrodt Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing